Allspring Global Investments Holdings LLC Reduces Stock Holdings in Humana Inc. $HUM

Key Points

• Allspring Global Investments Holdings LLC reduced its stake in Humana Inc. by 9.0% during the second quarter, owning 689,604 shares valued at approximately $174 million.
• Multiple institutional investors have increased their holdings in Humana, with OFI Invest Asset Management boosting its stake by 40.3% in the same quarter.
• Humana's stock has faced recent volatility, including a 3.6% decline, and the company reported earnings that missed estimates while projecting 2025 EPS guidance of $17.00.

Allspring Global Investments Holdings LLC decreased its stake in Humana Inc. (NYSE:HUM - Free Report) by 9.0% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 689,604 shares of the insurance provider's stock after selling 68,398 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.57% of Humana worth $174,180,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. OFI Invest Asset Management boosted its holdings in shares of Humana by 40.3% in the 2nd quarter. OFI Invest Asset Management now owns 390 shares of the insurance provider's stock worth $95,000 after purchasing an additional 112 shares during the period. Vanguard Personalized Indexing Management LLC lifted its stake in shares of Humana by 33.4% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 14,453 shares of the insurance provider's stock worth $3,534,000 after acquiring an additional 3,616 shares during the last quarter. Sivik Global Healthcare LLC lifted its stake in shares of Humana by 17.4% during the 2nd quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the insurance provider's stock worth $6,601,000 after acquiring an additional 4,000 shares during the last quarter. Fifth Third Wealth Advisors LLC lifted its stake in shares of Humana by 8.1% during the 2nd quarter. Fifth Third Wealth Advisors LLC now owns 1,337 shares of the insurance provider's stock worth $327,000 after acquiring an additional 100 shares during the last quarter. Finally, Aberdeen Group plc lifted its stake in shares of Humana by 30.8% during the 2nd quarter. Aberdeen Group plc now owns 172,161 shares of the insurance provider's stock worth $41,815,000 after acquiring an additional 40,492 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on HUM shares. Morgan Stanley decreased their price target on Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a research note on Thursday, July 31st. Royal Bank Of Canada lifted their target price on Humana from $283.00 to $322.00 and gave the company an "outperform" rating in a research report on Thursday, August 21st. Sanford C. Bernstein lifted their target price on Humana from $269.00 to $341.00 and gave the company an "outperform" rating in a research report on Friday, September 5th. Wall Street Zen lowered Humana from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, Wolfe Research lifted their target price on Humana from $283.00 to $313.00 and gave the company an "outperform" rating in a research report on Monday, October 6th. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Humana currently has a consensus rating of "Hold" and a consensus price target of $298.83.

Humana Stock Down 3.6%

Shares of HUM stock opened at $280.24 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.95 and a quick ratio of 1.95. The stock's fifty day moving average price is $279.45 and its 200 day moving average price is $258.04. The company has a market cap of $33.71 billion, a price-to-earnings ratio of 21.51, a price-to-earnings-growth ratio of 1.64 and a beta of 0.42. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $315.35.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). The firm had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. On average, research analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a $0.885 dividend. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.3%. Humana's dividend payout ratio is presently 27.17%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.